<DOC>
	<DOCNO>NCT00526734</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan , use different way stop cancer cell divide stop grow die . Stem cell transplant use stem cell patient may able replace immune cell destroy chemotherapy use kill cancer cell . Giving colony-stimulating factor , G-CSF pegfilgrastim , help stem cell move bone marrow blood collect . It yet know regimen effective treat multiple myeloma . PURPOSE : This randomized phase II trial study well high-dose chemotherapy follow stem cell transplant work treat patient newly diagnose stage I , stage II , stage III multiple myeloma .</brief_summary>
	<brief_title>High-Dose Chemotherapy Stem Cell Transplant Treating Patients With Newly Diagnosed Stage I , Stage II , Stage III Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare engraftment peripheral blood progenitor cell ( PBPCs ) mobilize 2 different fix dos pegfilgrastim versus by-weight dose filgrastim ( G-CSF ) . Secondary - Determine ability 2 different fix dos pegfilgrastim mobilize PBPCs . - Determine safety pegfilgrastim PBPC mobilization collection . - Determine effect different induction chemotherapy regimens autologous progenitor cell transplantation . OUTLINE : This multicenter study . Patients stratify type induction chemotherapy ( Thal/Dex vs VAD vs Vel-Dex v VTD ) stage disease accord International Prognostic Index criterion ( stage I [ i.e. , beta-2 microglobulin &lt; 3.5 albumin &gt; 35 ] v stage II III ) . - Induction therapy : Patients receive 3-4 course 1 follow regimen : - VAD : Patients receive vincristine , doxorubicin hydrochloride , dexamethasone . - Thal/Dex : Patients receive thalidomide dexamethasone . - Vel-Dex : Patients receive bortezomib dexamethasone . - VTD : Patients receive bortezomib , thalidomide , dexamethasone . Patients achieve complete , partial , minimal response 3-4 course induction therapy proceed peripheral blood progenitor cell ( PBPC ) mobilization 17 day completion induction therapy . - PBPC mobilization : Patients randomize 1 3 arm . - Arm I : Patients receive filgrastim subcutaneously ( SC ) daily final leukapheresis . - Arm II : Patients receive single dose pegfilgrastim SC . - Arm III : Patients receive pegfilgrastim arm II high dose . - Leukapheresis : Patients undergo 3 leukaphereses obtain adequate number CD34-positive filgrastim- pegfilgrastim-mobilized PBPCs engraftment . Patients achieve sufficient number collect PBSCs proceed condition chemotherapy . - Conditioning chemotherapy : Patients receive high-dose melphalan* IV 1-2 day . Patients proceed PBPC transplantation . NOTE : *Patients ≥ 65 year old receive melphalan low dose . - Autologous PBPC transplantation : Patients undergo infusion PBPCs day 0 . Patients arm receive G-CSF support begin day 1 PBPC transplantation continue blood count recover 3 consecutive day . After completion study therapy , patient follow 100 day post-transplantation .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis symptomatic stage I stage IIIII multiple myeloma Newly diagnose disease No amyloidosis PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 ANC ≥ 1.0 x 10^9/L ( without colonystimulating factor ) Platelet count ≥ 50 x 10^9/L ( without transfusion support within past 7 day ) Serum calcium &lt; 14 mg/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN Creatinine clearance ≥ 50 mL/min Fertile patient must use effective contraception Negative pregnancy test Willing able comply protocol requirement Exclusion criterion : Myocardial infarction within past 6 month New York Heart Association class III IV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Acute ischemia active conduction system abnormality evidence ECG Serious medical condition could prolong hematological recovery preclude completion tolerance protocol therapy Seropositive HIV antibody Known hepatitis B surface antigen positivity OR active hepatitis C infection Active systemic infection require treatment Pregnant nursing Poor psychiatric condition PRIOR CONCURRENT THERAPY : No plasmapheresis within past 4 week No major surgery within past 4 week No anticancer therapy within past 5 year , except treatment basal cell carcinoma skin carcinoma situ uterine cervix No concurrent GCSF growth factor No concurrent enrollment another investigational clinical trial No concurrent investigational agent would contraindicate use pegfilgrastim either mobilization agent hematological recovery agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>